Published in Cancer Res on May 11, 2010
The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta (2011) 1.64
The intracellular trafficking pathway of transferrin. Biochim Biophys Acta (2011) 1.36
Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology (2012) 0.98
Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget (2012) 0.95
Conjugation of functionalized SPIONs with transferrin for targeting and imaging brain glial tumors in rat model. PLoS One (2012) 0.86
Structure and dynamics of drug carriers and their interaction with cellular receptors: focus on serum transferrin. Adv Drug Deliv Rev (2012) 0.84
Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer. Ann Biomed Eng (2011) 0.83
Development of targeted therapies in treatment of glioblastoma. Cancer Biol Med (2015) 0.83
Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Interfaces (2015) 0.81
Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med (2012) 0.80
Internalization of biotinylated compounds into cancer cells is promoted by a molecular Trojan horse based upon core streptavidin and clostridial C2 toxin. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.77
Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem (2011) 0.77
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma. Sci Rep (2017) 0.75
Mathematical Modeling of Mutant Transferrin-CRM107 Molecular Conjugates for Cancer Therapy. J Theor Biol (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
Malignant gliomas in adults. N Engl J Med (2008) 20.54
Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 6.61
Receptor-mediated endocytosis of transferrin in K562 cells. J Biol Chem (1983) 3.65
Transferrin receptor on endothelium of brain capillaries. Nature (1984) 3.37
Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol (1983) 3.23
Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev (2002) 3.13
Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med (1997) 2.76
The transferrin receptor: role in health and disease. Int J Biochem Cell Biol (1999) 2.02
Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus (2006) 1.61
Two high-resolution crystal structures of the recombinant N-lobe of human transferrin reveal a structural change implicated in iron release. Biochemistry (1998) 1.57
Inhibition of transferrin iron release increases in vitro drug carrier efficacy. J Control Release (2006) 1.54
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol (2008) 1.47
Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol (2003) 1.46
Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood (1990) 1.34
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
Dual role of Lys206-Lys296 interaction in human transferrin N-lobe: iron-release trigger and anion-binding site. Biochemistry (1999) 1.27
Investigation of the mechanism of iron release from the C-lobe of human serum transferrin: mutational analysis of the role of a pH sensitive triad. Biochemistry (2003) 1.23
Novel drug delivery strategies in neuro-oncology. Neurotherapeutics (2009) 1.21
RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene (2005) 1.16
Differential effect of a his tag at the N- and C-termini: functional studies with recombinant human serum transferrin. Biochemistry (2002) 1.12
Expression, purification, and characterization of recombinant nonglycosylated human serum transferrin containing a C-terminal hexahistidine tag. Protein Expr Purif (2001) 1.09
Human serum transferrin: a tale of two lobes. Urea gel and steady state fluorescence analysis of recombinant transferrins as a function of pH, time, and the soluble portion of the transferrin receptor. J Biol Inorg Chem (2009) 1.06
The role of the diphtheria toxin receptor in cytosol translocation. J Biol Chem (1988) 1.03
Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. J Control Release (2008) 0.95
Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates. Cancer Res (1994) 0.93
Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg (1994) 0.90
Calorimetric studies of the binding of ferric ions to human serum transferrin. Biochemistry (1993) 0.88
Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation. Eur J Clin Invest (2002) 0.87
Transferrin receptors in human cancerous tissues. Tohoku J Exp Med (1987) 0.85
Iron transferrin receptors in rat and human cerebrum. Agressologie (1980) 0.81
Glioblastoma multiforme. Curr Treat Options Neurol (2009) 0.80
Targeted therapy for malignant gliomas. J Clin Neurosci (2004) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell (2011) 3.11
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 2.62
Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet (2005) 2.51
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell (2012) 2.45
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet (2013) 2.20
Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol (2011) 2.01
Non-stem cell origin for oligodendroglioma. Cancer Cell (2010) 1.95
Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med (2012) 1.89
Pleiotropic role for MYCN in medulloblastoma. Genes Dev (2010) 1.84
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79
Neuroblastoma and MYCN. Cold Spring Harb Perspect Med (2013) 1.75
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res (2006) 1.70
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res (2003) 1.67
Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell (2011) 1.67
EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal (2009) 1.66
Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging (2011) 1.65
BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res (2013) 1.64
Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev (2012) 1.64
The crystal structure of iron-free human serum transferrin provides insight into inter-lobe communication and receptor binding. J Biol Chem (2006) 1.60
Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A (2004) 1.57
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Inhibition of transferrin iron release increases in vitro drug carrier efficacy. J Control Release (2006) 1.54
Structural basis for iron piracy by pathogenic Neisseria. Nature (2012) 1.50
The intracellular cargo receptor ERGIC-53 is required for the production of infectious arenavirus, coronavirus, and filovirus particles. Cell Host Microbe (2013) 1.46
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol (2011) 1.42
Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc Natl Acad Sci U S A (2011) 1.42
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov (2012) 1.41
Involvement of RhoA, ROCK I and myosin II in inverted orientation of epithelial polarity. EMBO Rep (2008) 1.40
Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol (2012) 1.38
PI3K signaling in glioma--animal models and therapeutic challenges. Brain Pathol (2009) 1.36
The intracellular trafficking pathway of transferrin. Biochim Biophys Acta (2011) 1.36
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res (2009) 1.34
The long history of iron in the Universe and in health and disease. Biochim Biophys Acta (2011) 1.33
Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol (2012) 1.33
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res (2003) 1.32
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol (2011) 1.32
Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun (2013) 1.26
Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst (2003) 1.26
Polyarginine segments in block copolypeptides drive both vesicular assembly and intracellular delivery. Nat Mater (2006) 1.24
Investigation of the mechanism of iron release from the C-lobe of human serum transferrin: mutational analysis of the role of a pH sensitive triad. Biochemistry (2003) 1.23
Effect of glycosylation on the function of a soluble, recombinant form of the transferrin receptor. Biochemistry (2006) 1.23
Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J Neurooncol (2012) 1.23
The molecular mechanism for receptor-stimulated iron release from the plasma iron transport protein transferrin. Structure (2005) 1.16
RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene (2005) 1.16
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A (2012) 1.15
Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol (2010) 1.15
Intrinsic fluorescence reports a global conformational change in the N-lobe of human serum transferrin following iron release. Biochemistry (2007) 1.13
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
How the binding of human transferrin primes the transferrin receptor potentiating iron release at endosomal pH. Proc Natl Acad Sci U S A (2011) 1.12
Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One (2012) 1.11
Evolution of the transferrin family: conservation of residues associated with iron and anion binding. Comp Biochem Physiol B Biochem Mol Biol (2005) 1.11
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res (2007) 1.11
Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia (2008) 1.11
Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr (2006) 1.11
Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. Cancer Res (2005) 1.10
The unique kinetics of iron release from transferrin: the role of receptor, lobe-lobe interactions, and salt at endosomal pH. J Mol Biol (2009) 1.07
Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Curr Biol (2002) 1.07
Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. J Neuropathol Exp Neurol (2013) 1.06
Human serum transferrin: a tale of two lobes. Urea gel and steady state fluorescence analysis of recombinant transferrins as a function of pH, time, and the soluble portion of the transferrin receptor. J Biol Inorg Chem (2009) 1.06
Noncanonical interactions between serum transferrin and transferrin receptor evaluated with electrospray ionization mass spectrometry. Proc Natl Acad Sci U S A (2010) 1.05
Evidence that His349 acts as a pH-inducible switch to accelerate receptor-mediated iron release from the C-lobe of human transferrin. J Biol Inorg Chem (2010) 1.03
Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett (2011) 1.03
PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol (2012) 1.03
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol (2014) 1.02
Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res (2011) 1.02
A robust method to derive functional neural crest cells from human pluripotent stem cells. Am J Stem Cells (2013) 1.01
Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys (2010) 1.00
Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. Eur J Cancer (2007) 1.00
Kinetics of iron release from transferrin bound to the transferrin receptor at endosomal pH. Biochim Biophys Acta (2011) 1.00
Autophagy and Akt promote survival in glioma. Autophagy (2011) 0.99
Incorporation of multicellular spheroids into 3-D polymeric scaffolds provides an improved tumor model for screening anticancer drugs. Cancer Sci (2010) 0.98
Proteoglycans and their roles in brain cancer. FEBS J (2013) 0.98
Current management of choroid plexus carcinomas. Neurosurg Rev (2013) 0.98
High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors. Pediatr Blood Cancer (2004) 0.97
Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med (2012) 0.97
Tuberculoma of the central nervous system. J Clin Neurosci (2013) 0.96
Interlobe communication in human serum transferrin: metal binding and conformational dynamics investigated by electrospray ionization mass spectrometry. Biochemistry (2003) 0.96
Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Semin Cancer Biol (2011) 0.96
The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Mod Pathol (2013) 0.96
Composition of pH-sensitive triad in C-lobe of human serum transferrin. Comparison to sequences of ovotransferrin and lactoferrin provides insight into functional differences in iron release. Biochemistry (2005) 0.96